Sickle Cell Disorders clinical trials at UCSF
1 research study open to eligible people
Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease
open to eligible people ages 6 years and up
This is an open label extension study in subjects with Sickle Cell Disease (SCD) who have completed the double blind Phase 3 study (B5201002).
Oakland, California and other locations